RenovoRx Past Earnings Performance
Past criteria checks 0/6
RenovoRx's earnings have been declining at an average annual rate of -28.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-28.9%
Earnings growth rate
20.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
Mar 31
Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Dec 16RenovoRx reports Q2 results
Aug 15Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
Aug 04RenovoRx names new finance CFO
Jul 19RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
Mar 16We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
Nov 30Revenue & Expenses BreakdownBeta
How RenovoRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -10 | 6 | 6 |
| 30 Sep 23 | 0 | -9 | 6 | 6 |
| 30 Jun 23 | 0 | -10 | 6 | 5 |
| 31 Mar 23 | 0 | -10 | 6 | 4 |
| 31 Dec 22 | 0 | -10 | 6 | 4 |
| 30 Sep 22 | 0 | -10 | 6 | 5 |
| 30 Jun 22 | 0 | -9 | 5 | 5 |
| 31 Mar 22 | 0 | -8 | 4 | 4 |
| 31 Dec 21 | 0 | -6 | 3 | 3 |
| 30 Sep 21 | 0 | -5 | 2 | 2 |
| 30 Jun 21 | 0 | -4 | 1 | 2 |
| 31 Mar 21 | 0 | -4 | 1 | 2 |
| 31 Dec 20 | 0 | -4 | 1 | 2 |
Quality Earnings: RNXT is currently unprofitable.
Growing Profit Margin: RNXT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNXT is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare RNXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: RNXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.